Real-World Data

Advances in the availability of real-world data (RWD) sources – such as electronic health records, registries, or feedback from wearables and mobile technology – have increased the potential to evaluate implementation of innovative diagnostics or therapeutic applications in regular care. These range from preventive interventions through biomarker-validation and innovative systemic -and technological interventions to survivorship care.

As such, knowledge on outcome of various kinds of interventions in populations outside clinical trials, is obtained. Added to that, it creates a deeper understanding of their economic implications through Health Technology Assessment. 

Our real-world data (RWD) infrastructure integrates research into routine care, enabling us to learn from each patient and improve their outcomes.

RWD infrastructure

Patients or their representatives for children and caregivers for animals, are systematically asked to consent to the use of clinical data, patient-reported outcomes and evaluation, and blood/tissue banking. This consent is performed via an (e-)consult at the “innovation clinic” or during regular hospital visits. Patients may give broad consent for future studies, allowing them to be offered future experimental interventions if eligible This approach generates large representative, GDPR proof study populations and serves as a multi-trial facility for comparison of effectiveness of new interventions against standard care as well as insight in survivorship issues. 

Next generation experts

Our responsibility includes educating and training the next generation of researchers to create a dynamic environment in which innovative science will continue contributing to an ever-improving outcome for our patients.


Within the Graduate School of Life Sciences we offer the following PhD programme tailored to this goal: 

 Students can also visit our other PhD programmes or Master's programmes